Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Queensland Health
Healthtrust
QuintilesIMS
Julphar
Daiichi Sankyo
US Army
Cipla
Covington

Generated: June 21, 2018

DrugPatentWatch Database Preview

INCRUSE ELLIPTA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Incruse Ellipta patents expire, and what generic alternatives are available?

Incruse Ellipta is a drug marketed by Glaxo Grp England and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-nine countries.

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.
Summary for INCRUSE ELLIPTA
International Patents:158
US Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 24
Clinical Trials: 26
Patent Applications: 82
DailyMed Link:INCRUSE ELLIPTA at DailyMed
Drug patent expirations by year for INCRUSE ELLIPTA
Pharmacology for INCRUSE ELLIPTA
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists
Synonyms for INCRUSE ELLIPTA
1-(2-(Benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)-1-azoniabicyclo(2.2.2)octane bromide
1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide
1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide
1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2-(phenylmethoxy)ethyl)-, bromide (1:1)
1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1)
4-[Hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane Bromide
7AN603V4JV
869113-09-7
AK174796
AKOS025404842
bromure d'umeclidinium
bromuro de umeclidinio
CHEBI:79040
CHEMBL523299
CS-0874
D09ZOQ
D10181
diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide
DTXSID50235966
EX-A1683
GSK-573719
GSK-573719A
GSK573719A
HY-12100
Incruse ellipta (TN)
KB-81385
KS-00001CW3
MolPort-039-137-700
PEJHHXHHNGORMP-UHFFFAOYSA-M
SCHEMBL109931
umeclidinii bromidum
Umeclidinium (bromide)
Umeclidinium brom
Umeclidinium bromide
Umeclidinium bromide (JAN/USAN)
Umeclidinium bromide [USAN:INN]
Umeclidinium bromide(GSK573719A)
Umeclidinium(bromide)
UNII-7AN603V4JV
VA12030

US Patents and Regulatory Information for INCRUSE ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for INCRUSE ELLIPTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,144,571 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
8,575,347 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
9,045,469 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
8,853,404 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for INCRUSE ELLIPTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0075 France ➤ Sign Up PRODUCT NAME: BROMURE D'UMECLIDINIUM; REGISTRATION NO/DATE: EU/1/14/922 001-003 20140428
0140032 00132 Estonia ➤ Sign Up PRODUCT NAME: UMEKLIDIINBROMIID;REG NO/DATE: EU/1/14/922 30.04.2014
0694 Netherlands ➤ Sign Up PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430
1740177/02 Switzerland ➤ Sign Up PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Cantor Fitzgerald
Covington
Baxter
Deloitte
Mallinckrodt
AstraZeneca
Chinese Patent Office
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.